{"log_id": 1213348685524977189, "direction": 0, "words_result_num": 26, "words_result": [{"probability": {"variance": 0.021512, "average": 0.944089, "min": 0.352152}, "location": {"width": 941, "top": 140, "height": 27, "left": 134}, "words": "对轻度(肌酐清除率[CLcr]为60至90ml/分钟)和中度(CIc为30至60ml/分钟)肾损害的患者不需要"}, {"probability": {"variance": 0.000739, "average": 0.992137, "min": 0.817781}, "location": {"width": 941, "top": 169, "height": 27, "left": 135}, "words": "进行首次剂量调整。尚无法确定严重肾损害患者是否需要进行首次剂量调整。而且,目前尚无终末期肾脏"}, {"probability": {"variance": 0.010588, "average": 0.964431, "min": 0.405403}, "location": {"width": 941, "top": 197, "height": 28, "left": 135}, "words": "疾病患者的数据。因此,严重肾损害[CIcr小于30ml/分钟)的患者或终末期肾脏疾病患者使用克唑替尼胶"}, {"probability": {"variance": 0.012615, "average": 0.968941, "min": 0.481453}, "location": {"width": 409, "top": 225, "height": 26, "left": 135}, "words": "囊进行治疗时应谨慎。(见【药代动力学】)"}, {"probability": {"variance": 0.000202, "average": 0.992601, "min": 0.96099}, "location": {"width": 107, "top": 290, "height": 26, "left": 141}, "words": "【不良反应】"}, {"probability": {"variance": 0.000147, "average": 0.994213, "min": 0.938961}, "location": {"width": 894, "top": 323, "height": 26, "left": 180}, "words": "安全性数据主要来自两项单臂的多中心临床研究(研究A8081005和研究A8081001)。两项与现有"}, {"probability": {"variance": 3.9e-05, "average": 0.99664, "min": 0.963533}, "location": {"width": 931, "top": 351, "height": 26, "left": 137}, "words": "化疗比较的随机对照临床研究(研究A8081007和研究A8081014)尚在进行中,仅获得初步安全性数据"}, {"probability": {"variance": 2.6e-05, "average": 0.996305, "min": 0.972972}, "location": {"width": 550, "top": 379, "height": 25, "left": 134}, "words": "在研究A8081005、A8081007和A8081014中包括了中国患者"}, {"probability": {"variance": 3.8e-05, "average": 0.997839, "min": 0.964041}, "location": {"width": 900, "top": 417, "height": 28, "left": 177}, "words": "由于各个临床研究的情况不尽相同,直接比较两种药物在不同临床研究中的不良反应发生率是不恰当"}, {"probability": {"variance": 7e-06, "average": 0.99863, "min": 0.985818}, "location": {"width": 639, "top": 446, "height": 26, "left": 135}, "words": "的,临床研究中的不良反应发生率也可能与临床实践中的情况有所不同"}, {"probability": {"variance": 0.00091, "average": 0.98541, "min": 0.797504}, "location": {"width": 899, "top": 484, "height": 30, "left": 177}, "words": "在研究A8081005和研究A8081001中,ALK阳性的局部晚期或转移的非小细胞肺癌患者口服250mg"}, {"probability": {"variance": 0.00071, "average": 0.992844, "min": 0.81284}, "location": {"width": 938, "top": 513, "height": 25, "left": 135}, "words": "克唑替尼胶囊,每日两次,连续用药。在截至2010年11月获得255例ALK阳性的局部晚期或转移的非"}, {"probability": {"variance": 0.00205, "average": 0.985572, "min": 0.764038}, "location": {"width": 941, "top": 540, "height": 27, "left": 137}, "words": "小细胞肺癌患者安全性数据中,两项研究平均用药时间分别为5.1个月和7.8个月,中断用药的患者分别"}, {"probability": {"variance": 3.7e-05, "average": 0.996139, "min": 0.970195}, "location": {"width": 922, "top": 567, "height": 27, "left": 136}, "words": "为36%和45%,中断用药持续时间超过两周的患者分别为13%和19在研究A8081005和A8081001中"}, {"probability": {"variance": 0.00673, "average": 0.978449, "min": 0.530618}, "location": {"width": 944, "top": 596, "height": 25, "left": 136}, "words": "减量的患者分别为44%和29%。药物治疗相关的不良事件引起的永久停药的发生率分别为6%和3%。在两"}, {"probability": {"variance": 0.000456, "average": 0.992805, "min": 0.865476}, "location": {"width": 943, "top": 622, "height": 27, "left": 136}, "words": "项研究中最常见的不良反应(25%)为视觉异常、恶心、腹泻、呕吐、水肿和便秘。在两项研究中均有至"}, {"probability": {"variance": 1.3e-05, "average": 0.997952, "min": 0.982329}, "location": {"width": 618, "top": 650, "height": 26, "left": 136}, "words": "少4%的患者出现的3级和4级不良反应包括ALT和中性粒细胞减少"}, {"probability": {"variance": 0.000604, "average": 0.992944, "min": 0.850628}, "location": {"width": 905, "top": 688, "height": 27, "left": 177}, "words": "在可获得死亡和严重不良反应信息的397例患者中,45例患者在末次给药后28天内出现死亡。10例"}, {"probability": {"variance": 0.001005, "average": 0.98916, "min": 0.792983}, "location": {"width": 927, "top": 716, "height": 27, "left": 152}, "words": "2.5%)患者在试验药物首次给药后28天内出现死亡。死亡原因包括疾病进展(32例)、呼吸系统事件(9"}, {"probability": {"variance": 0.000824, "average": 0.992834, "min": 0.799977}, "location": {"width": 943, "top": 743, "height": 26, "left": 136}, "words": "例)及其他(4例)。导致死亡的呼吸系统的原因包括肺炎(2例)、缺氧(2例)、急性呼吸窘迫综合征"}, {"probability": {"variance": 0.000662, "average": 0.988335, "min": 0.87442}, "location": {"width": 929, "top": 770, "height": 27, "left": 153}, "words": "ARDS)(1例)、呼吸困难(1例)非感染性肺炎(1例)、脓胸(1例)和肺出血(1例)。死亡的其"}, {"probability": {"variance": 0.004549, "average": 0.978263, "min": 0.598334}, "location": {"width": 941, "top": 795, "height": 33, "left": 135}, "words": "他原因包括脓毒性休克、弥漫性血管内凝血(DIC)、心血管事件和原因不明的死各1例至少2%"}, {"probability": {"variance": 9.3e-05, "average": 0.996191, "min": 0.958527}, "location": {"width": 517, "top": 823, "height": 29, "left": 135}, "words": "的患者发生的严重不良事件包括肺炎、呼吸困难和肺栓塞"}, {"probability": {"variance": 0.053606, "average": 0.68213, "min": 0.375384}, "location": {"width": 861, "top": 858, "height": 49, "left": 176}, "words": "460501唑后的常反应"}, {"probability": {"variance": 0, "average": 0.707368, "min": 0.707368}, "location": {"width": 134, "top": 924, "height": 69, "left": 548}, "words": "★"}, {"probability": {"variance": 0, "average": 0.752501, "min": 0.752501}, "location": {"width": 44, "top": 963, "height": 36, "left": 707}, "words": "A"}], "language": 3}